Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

AIM To evaluate the effectiveness of probiotic therapy for suppressing relapse in patients with inactive ulcerative colitis (UC). METHODS Bio-Three tablets, each containing 2 mg of lactomin (Streptococcus faecalis T-110), 10 mg of Clostridium butyricum TO-A, and 10 mg of Bacillus mesentericus TO-A, were used as probiotic therapy. Sixty outpatients with UC in remission were randomly assigned to receive 9 Bio-Three tablets/day (Bio-Three group) or 9 placebo tablets/day (placebo group) for 12 mo in addition to their ongoing medications. Clinical symptoms were evaluated monthly or on the exacerbation of symptoms or need for additional medication. Fecal samples were collected to analyze bacterial DNA at baseline and 3-mo intervals. Terminal restriction fragment length polymorphism and cluster analyses were done to examine bacterial components of the fecal microflora. RESULTS Forty-six patients, 23 in each group, completed the study, and 14 were excluded. The relapse rates in the Bio-Three and placebo groups were respectively 0.0% vs 17.4% at 3 mo (P = 0.036), 8.7% vs 26.1% at 6 mo (P = 0.119), and 21.7% vs 34.8% (P = 0.326) at 9 mo. At 12 mo, the remission rate was 69.5% in the Bio-Three group and 56.6% in the placebo group (P = 0.248). On cluster analysis of fecal flora, 7 patients belonged to cluster I, 32 to cluster II, and 7 to cluster III. CONCLUSION Probiotics may be effective for maintaining clinical remission in patients with quiescent UC, especially those who belong to cluster I on fecal bacterial analysis.

• Publication year

  2015

• Venue

  World Journal of Gastroenterology

• Publication date

  2015-05-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.3748/wjg.v21.i19.5985PMID 26019464PMCID PMC4438034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut

  2013cited by this paper
• A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis.

  2011cited by this paper
• Probiotics for maintenance of remission in ulcerative colitis.

  2011cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• Beneficial Effects of Probiotic Bifidobacterium and Galacto-Oligosaccharide in Patients with Ulcerative Colitis: A Randomized Controlled Study

  2011cited by this paper
• Butyrate enemas do not affect human colonic MUC2 and TFF3 expression

  2010cited by this paper
• Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis.

  2010cited by this paper
• Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission.

  2010cited by this paper
• A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis.

  2009cited by this paper
• Bacterial population moves toward a colon-like community in the pouch after total proctocolectomy.

  2009cited by this paper
• Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis

  2009cited by this paper
• Bacterial community diversity in cultures derived from healthy and inflamed ileal pouches after restorative proctocolectomy

  2009cited by this paper
• Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43

  2009cited by this paper
• Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol®

  2009cited by this paper
• A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon.

  2007cited by this paper
• Probiotics for induction of remission in ulcerative colitis.

  2007cited by this paper
• Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy

  2007cited by this paper
• Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease

  2007cited by this paper
• Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis

  2007cited by this paper
• Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study.

  2006cited by this paper
• Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

  2005cited by this paper
• Neural and non‐neural mediation of propionate‐induced contractile responses in the rat distal colon

  2005cited by this paper
• Propionate modulates spontaneous contractions via enteric nerves and prostaglandin release in the rat distal colon.

  2005cited by this paper
• VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

  2005cited by this paper
• VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics.

  2005cited by this paper
• Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study

  2005cited by this paper
• The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease.

  2005cited by this paper
• Movement and Fixation of Intestinal Microbiota after Administration of Human Feces to Germfree Mice

  2005cited by this paper
• Mucosal bacteria in ulcerative colitis

  2005cited by this paper
• Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

  2004cited by this paper
• Short-chain fatty acids decrease the frequency of spontaneous contractions of longitudinal muscle via enteric nerves in rat distal colon.

  2004cited by this paper
• Bacterial milieu and mucosal bacteria in ulcerative colitis.

  2004cited by this paper
• Probiotics, prebiotics and antibiotics in inflammatory bowel disease.

  2004cited by this paper
• Inflammatory bowel disease: the role of environmental factors.

  2004cited by this paper
• Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

  2004cited by this paper
• Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis

  2003cited by this paper
• Modification of intestinal flora in the treatment of inflammatory bowel disease.

  2003cited by this paper
• Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

  2003cited by this paper
• Application of New Primer-Enzyme Combinations to Terminal Restriction Fragment Length Polymorphism Profiling of Bacterial Populations in Human Feces

  2003cited by this paper
• Terminal Restriction Fragment Length Polymorphism Analysis for Human Fecal Microbiota and Its Application for Analysis of Complex Bifidobacterial Communities

  2003cited by this paper
• A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis

  2002cited by this paper
• Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells

  2002cited by this paper
• Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial

  2002cited by this paper
• Bacteria as the cause of ulcerative colitis

  2001cited by this paper
• Allopurinol in addition to 5‐aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis

  2000cited by this paper
• Counter‐regulatory effect of sodium butyrate on tumour necrosis factor‐alpha (TNF‐α)‐induced complement C3 and factor B biosynthesis in human intestinal epithelial cells

  1999cited by this paper
• Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study

  1998cited by this paper
• In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis.

  1998cited by this paper
• Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months

  1998cited by this paper
• Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA

  1997cited by this paper
• Treatment of left‐sided ulcerative colitis with butyrate enemas: a controlled trial

  1996cited by this paper
• Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.

  1995cited by this paper
• Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis

  1995cited by this paper
• Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

  1992cited by this paper
• Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.

  1992cited by this paper
• Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.

  1988cited by this paper

• Lactobacillus delbrueckii surface protein P4430 attenuates intestinal inflammation by modulating macrophage polarization via Mincle.

  2026cites this paper
• Probiotic strain Bacillus subtilis TO-A modulates the formation of neutrophil extracellular traps

  2025cites this paper
• Screening and Genetic Analysis of Bifidobacterium longum subsp. Longum dipro-X for IBD Alleviation.

  2025cites this paper
• Probiotics in IBD: Evidence and Perspectives on Patient Health and Disease Management

  2025cites this paper
• Therapeutic Potential of Probiotics: A Review of Their Role in Modulating Inflammation.

  2025cites this paper
• Systematic Review of the Effectiveness of Common Probiotic Strains: Streptococcus faecalis, Clostridium butyricum, Bacillus mesentericus, and Lactobacillus sporogenes in the Management of Diabetes

  2025cites this paper
• Combination of probiotics enhancing butyrogenesis in colonic microbiota model of patients with ulcerative colitis

  2025cites this paper
• New targets for the treatment of ulcerative colitis: Gut microbiota and its metabolites

  2025cites this paper
• Safety of Clostridium butyricum TO‐A as a novel food pursuant to Regulation (EU) 2015/2283

  2025cites this paper
• Gut microbiota and intestinal immunity interaction in ulcerative colitis and its application in treatment

  2025cites this paper
• Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence

  2025cites this paper
• Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools

  2025cites this paper
• The Role of Gut Microbiota and Probiotics in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• Effect of Bacillus clausii in attenuating symptoms of DSS‐induced ulcerative colitis by modulating NFkB pathway and oxidative stress in mice

  2024cites this paper
• Gut microbiome‐targeted therapies as adjuvant treatments in inflammatory bowel diseases: a systematic review and network meta‐analysis

  2024cites this paper
• Probiotic Potential in Irritable Bowel Syndrome and Inflammatory Bowel Disease: A Comprehensive Systematic Review

  2024influential citation
• Lactic Acid Bacteria–Gut-Microbiota-Mediated Intervention towards Inflammatory Bowel Disease

  2024cites this paper
• Prevention of Recurrent Spontaneous Preterm Delivery Using Probiotics (Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis; PPP Trial): Protocol for a Prospective, Single-Arm, Nonblinded, Multicenter Trial

  2024cites this paper
• Immunomodulatory Effects of a Probiotic Mixture: Alleviating Colitis in a Mouse Model through Modulation of Cell Activation Markers and the Gut Microbiota

  2024cites this paper
• Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta‐analysis of randomized controlled trials

  2024cites this paper
• Guía colombiana para el uso de probióticos en patologías pediátricas

  2024cites this paper
• A Comprehensive Review of Dietary Approaches in Maintaining Remission of Inflammatory Bowel Diseases in Adults

  2024cites this paper
• A Comprehensive Analysis of Efficacy and Safety of Probiotics in Inflammatory Bowel Disease

  2024cites this paper
• The Impact of Microbiome Interventions on the Progression and Severity of Inflammatory Bowel Disease: A Systematic Review

  2024cites this paper
• Probiotics for inflammatory bowel disease: Is there sufficient evidence?

  2024cites this paper
• Human-derived bacterial strains mitigate colitis via modulating gut microbiota and repairing intestinal barrier function in mice

  2024cites this paper
• Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials

  2024cites this paper
• Additive efficacy and safety of probiotics in the treatment of ulcerative colitis: a systematic review and meta-analysis

  2024cites this paper
• ESPEN guideline on Clinical Nutrition in inflammatory bowel disease.

  2023cites this paper
• Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis

  2023cites this paper
• Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease

  2023cites this paper
• Effects of Probiotics in Adults with Gastroenteritis: A Systematic Review and Meta-Analysis of Clinical Trials

  2023influential citation
• Investigation of the anti-inflammatory effects of native potential probiotics as supplementary therapeutic agents in an in-vitro model of inflammation

  2023cites this paper
• Systematic review: does the use of probiotics generate benefits for patients treating inflammatory intestinal disease?

  2023cites this paper
• Does probiotic supplementation improve quality of life in mild-to-moderately active ulcerative colitis patients in Jordan? A secondary outcome of the randomized, double-blind, placebo-controlled study

  2023cites this paper
• The Role of Probiotics in Inducing and Maintaining Remission in Crohn’s Disease and Ulcerative Colitis: A Systematic Review of the Literature

  2023cites this paper
• Role of lactobacillus strains in the management of colorectal cancer: An overview of recent advances.

  2022cites this paper
• Synbiotics in the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications

  2022cites this paper
• Trust your gut: The human microbiome

  2022cites this paper
• Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics

  2022cites this paper
• Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease

  2022cites this paper
• British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease

  2022cites this paper
• Nutraceuticals in the Treatment of Inflammatory Bowel Disease: How the Panorama has Changed in the Last Decade?

  2022cites this paper
• Efficacy of Probiotics-Based Interventions as Therapy for Inflammatory Bowel Disease: A Recent Update

  2022cites this paper
• Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis

  2022cites this paper
• Therapeutic applications of probiotics and its regulatory framework

  2022cites this paper
• Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease

  2022cites this paper
• Decreased mucosal adhesion of Lactobacillus species in patients with inflammatory bowel disease

  2022cites this paper
• Autoimmune-associated genetics impact probiotic colonization of the infant gut.

  2022cites this paper
• Sodium butyrate treatment and fecal microbiota transplantation provide relief from ulcerative colitis-induced prostate enlargement

  2022cites this paper
• Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications

  2022cites this paper
• Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease

  2022cites this paper
• Assessment of probiotic adhesion and inhibitory effect on Escherichia coli and Salmonella adhesion

  2021cites this paper
• Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis

  2021cites this paper
• The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010–20

  2021cites this paper
• Clostridium butyricum Supernatant Regulates the Expression of RORγt in HCT-116 Cells by Inhibiting the TLR2/MyD88/NF-κB Signaling Pathway

  2021cites this paper
• Effect of probiotics on gingival inflammation and oral microbiota: a meta-analysis.

  2021cites this paper
• Probiotic Therapy (BIO-THREE) Mitigates Intestinal Microbial Imbalance and Intestinal Damage Caused by Oxaliplatin

  2021cites this paper
• The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis

  2021cites this paper
• Gut mucosal and adipose tissues as health targets of the immunomodulatory mechanisms of probiotics

  2021cites this paper
• Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study

  2021cites this paper
• Toll-Like Receptors as Drug Targets in the Intestinal Epithelium.

  2021cites this paper
• The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies

  2021cites this paper
• Effects of probiotics on inflammatory bowel disease: A systematic review

  2021cites this paper
• Treatment of Inflammatory Bowel Disease: A Comprehensive Review

  2021cites this paper
• Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD

  2021cites this paper
• Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

  2020cites this paper
• Direct evidence of preventive effect of severe diarrhea in calf by milk replacer-based probiotic feeding

  2020cites this paper
• The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009–2020

  2020cites this paper
• Probiotics for maintenance of remission in ulcerative colitis.

  2020cites this paper
• Probiotics in Inflammatory Bowel Disease: Are We Back to Square One?

  2020cites this paper
• Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults—A Meta-Analytical Study

  2020cites this paper
• Effectiveness of probiotics, prebiotics, and prebiotic-like components in common functional foods.

  2020cites this paper
• AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.

  2020cites this paper
• Protective Effects of Clostridium Butyricum in a Murine Model of Dextran Sodium Sulfate-Induced Colitis That Involve Inhibition of the TLR2 Signaling Pathway and T Helper 17 Cells.

  2020cites this paper
• Therapeutic applications of probiotics in ulcerative colitis: An updated review

  2020cites this paper
• The gut microbiome: what every gastroenterologist needs to know

  2020cites this paper
• ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease.

  2020cites this paper
• Side Effects Associated with Probiotic Use in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa

  2019cites this paper
• Combination of probiotics with different functions alleviate DSS-induced colitis by regulating intestinal microbiota, IL-10, and barrier function

  2019cites this paper
• Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation

  2019cites this paper
• Perioperative dietary therapy in inflammatory bowel disease.

  2019cites this paper
• Giving probiotics to your children for gastrointestinal problems: In the light of scientific findings

  2019cites this paper
• First and second generation probiotic therapeutics for Inflammatory Bowel Disease

  2019cites this paper
• AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

  2019cites this paper
• An introduction of the role of probiotics in human infections and autoimmune diseases

  2019influential citation
• Cutting Edge: Probiotics and Fecal Microbiota Transplantation in Immunomodulation

  2019cites this paper
• Efficacy and safety of probiotics in adults with ulcerative colitis: A meta-analysis of placebo-controlled trials

  2019cites this paper
• Novel Approaches for Pouchitis and Colitis With or Without Diversion

  2019cites this paper
• Safety of Probiotics in Health and Disease

  2019cites this paper
• Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective

  2019cites this paper
• Construction of a Model Culture System of Human Colonic Microbiota to Detect Decreased Lachnospiraceae Abundance and Butyrogenesis in the Feces of Ulcerative Colitis Patients.

  2019cites this paper
• European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease.

  2019cites this paper
• Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity.

  2019cites this paper
• The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis

  2019cites this paper
• Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

  2019cites this paper
• Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease – An Overview of Human Studies

  2019cites this paper
• Effectiveness of probiotics for antipsychotic-induced functional bowel disorders: A single-center retrospective observational study

  2019cites this paper
• Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis

  2018cites this paper